【摘要】 背景与目的 DNA修复基因多态性预测铂类药物化疗敏感性对非小细胞肺癌（non-small cell lung cancer, NSCLC）个体化治疗具有重要意义。本研究旨在探讨X线修复交错互补基因1（X-ray repair cross complementing gene 1, XRCC1）和X线修复交错互补基因3（X-ray repair cross complementing gene 3, XRCC3）单核苷酸多态性与晚期NSCLC患 'an XU,.com 【Abstract】 Background and objective DNA repair gene polymorphisms can be used to predict the sensitivity of platinum-based chemotherapy. Thus, such polymorphisms are important for the individual treatment of non-small cell lung cancer (NSCLC). The aim of this study is to investigate the relationship between X-ray repair cross complementing protein 1 (XRCC1) and X-ray repair cross complementing protein 3 (XRCC3) gene polymorphisms and the chemosensitivity of platinum-based chemotherapy in patients with advanced NSCLC. Methods Genomic DNA were extracted from the sera of a total of 130 patients with advanced NSCLC who received platinum-based chemotherapy. XRCC1 Arg194 Trp, Arg399 Gln, and XRCC3 Thr241 Met were genotyped using the polymerase chain reaction-restriction fragment length polymorphism method, and the relationship between XRCC1 and XRCC3 polymorphisms and chemotherapy sensitivity was analyzed. 
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中 国 肺 癌 杂 志 2 0 1 1 年 1 2 月 第 1 4 卷 第 1 2 期 Chin J Lung Cancer, December 2011, Vol.14, No.12 observed. The objective response rate of the patients with at least one XRCC1 www.lungca.org 易感性相关 [16, 17] 。而XRCC3 Thr241 Met的SNP与铂类药 物化疗敏感性关系的研究较少，国内仅见任胜祥等 [18] 报告了ERCC1和XRCC3 241基因多态性在接受含铂方案 
